Cite
Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial.
MLA
Gullestad, Lars, et al. “Long-Term Outcomes of Thoracic Transplant Recipients Following Conversion to Everolimus with Reduced Calcineurin Inhibitor in a Multicenter, Open-Label, Randomized Trial.” Transplant International : Official Journal of the European Society for Organ Transplantation, vol. 29, no. 7, July 2016, pp. 819–29. EBSCOhost, https://doi.org/10.1111/tri.12783.
APA
Gullestad, L., Eiskjaer, H., Gustafsson, F., Riise, G. C., Karason, K., Dellgren, G., Rådegran, G., Hansson, L., Gude, E., Bjørtuft, Ø., Jansson, K., Schultz, H. H., Solbu, D., & Iversen, M. (2016). Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial. Transplant International : Official Journal of the European Society for Organ Transplantation, 29(7), 819–829. https://doi.org/10.1111/tri.12783
Chicago
Gullestad, Lars, Hans Eiskjaer, Finn Gustafsson, Gerdt C Riise, Kristjan Karason, Göran Dellgren, Göran Rådegran, et al. 2016. “Long-Term Outcomes of Thoracic Transplant Recipients Following Conversion to Everolimus with Reduced Calcineurin Inhibitor in a Multicenter, Open-Label, Randomized Trial.” Transplant International : Official Journal of the European Society for Organ Transplantation 29 (7): 819–29. doi:10.1111/tri.12783.